AR and posterior cortical atrophy: Taken together, this study moved the field forward by providing strong evidence to employ parallel treatment regimens with BETi or/and AR targeted therapeutics for the clinical management of DLX1-positive PCa subtype, hence opening new treatment avenues for patients with advanced-stage disease.